Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia

Trial Timeline

Apr 7, 2009 → Sep 1, 2016

NCT ID

NCT01412398

About Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet is a pre-clinical stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01412398. Target conditions include Hyperphosphatemia.

What happened to similar drugs?

2 of 15 similar drugs in Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (13)

✅Tenapanor + Sevelamer CarbonateArdelyxApproved

✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved

🔄KHK7791 + PlaceboKyowa KirinPhase 3

🔄KHK7791Kyowa KirinPhase 3

🔄SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01412398	Pre-clinical	Completed	Apr 7, 2009	Sep 1, 2016	Hyperphosphatemia
NCT01419327	Pre-clinical	Completed	Mar 23, 2009	May 28, 2019	Hyperphosphatemia

Competing Products

20 competing products in Hyperphosphatemia

See all competitors

Product	Company	Stage	Hype Score
EOS789 + Placebo + Renvela	Chugai Pharmaceutical	Phase 1	29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet	Daiichi Sankyo	Phase 1	29
ASP1585 + Placebo + Sevelamer hydrochloride	Astellas Pharma	Phase 2	35
ASP1585	Astellas Pharma	Phase 2	35
the standard-dose group (4 g/day)	Kyowa Kirin	Pre-clinical	33
KHK7791 + Placebp	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 2	35
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)	Kyowa Kirin	Pre-clinical	33
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
KHK7791	Kyowa Kirin	Phase 3	40
KHK7791 + Placebo	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 3	40
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl	Novartis	Phase 2	35
SBR759A + SBR759A + SBR759A + SBR759A + SBR759A	Novartis	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
Placebo + Sevelamer Carbonate (GZ419831)	Sanofi	Phase 3	40
Placebo + Sevelamer carbonate	Sanofi	Phase 2	35
Lanthanum Carbonate (Fosrenol, BAY77-1931)	Bayer	Pre-clinical	23
Lanthanum Carbonate (BAY77-1931)	Bayer	Phase 2	32